Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 8K citations · Full text

Life Sciences, Immunology, Oncology +17

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations

Medicine, Oncology, Pharmacology +17

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations

Medicine, Cancer Biology, Oncology +15

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Sandra Misale, Rona Yaeger, Sebastijan Hobor et al. · Nature · 2012 · 1.9K citations · Full text

Medicine, Molecular Genetics, Oncology +16